Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0206061 (
interstitial pneumonia
)
6,105
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Recombinant glycosylated
erythropoietin
(
EPO
) was biotinylated with biotin-aminocaproyl hydrazide via periodate-treated sialic acid moieties and applied to sections of 64 tumors of the lower respiratory tract, comprising 19 primary adenocarcinomas, 19 epidermoid carcinomas, 13 large cell anaplastic carcinomas, 11 small cell lung carcinomas, 11 intrapulmonary metastases, 1 mesothelioma and 1 lymphocytic
interstitial pneumonia
. The formalin-fixed, paraffin-embedded specimens were incubated with labelled
EPO
at room temperature and a concentration of 10 micrograms/ml for 60 min. The expression of the
EPO
-binding sites was visualized by the ABC technique. All of the analyzed large cell anaplastic carcinomas and the majority of the epidermoid carcinoma (89%), adenocarcinoma (79%), and metastases (82%) displayed binding capacities for
EPO
. Five out of the eleven small cell lung carcinomas, the analyzed mesothelioma and lymphocytic
interstitial pneumonia
revealed definite staining, too. Binding sites could, in addition, be seen in air dried, non-fixed, acetone-fixed, and ether-ethanol-fixed cytological specimens. The data indicate that the expression of binding sites with specificity for
EPO
can be frequently seen in human bronchial malignancies.
...
PMID:Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. 142 Jan 6
The mechanisms of erythrocyte recovery after BMT are not known. We investigated the respective role of marrow function and
erythropoietin
production in 31 ABMT and 47 allogeneic BMT by analysing peripheral counts, serum
erythropoietin
levels, and serum transferrin receptor (TfR) levels which have been shown to be a quantitative measurement of erythropoiesis. Median times to complete neutrophil (25 vs 48 days, p < 0.0001) and platelet (45 vs 263 days, p < 0.001) recovery were faster after allogeneic BMT than ABMT, but complete erythrocyte recovery was slower (218 vs 101 days, p < 0.001). After ABMT, erythrocyte recovery paralleled that of neutrophils and platelets, and
erythropoietin
levels remained appropriate for the degree of anemia. After allogeneic BMT, erythrocytes developed independently of the other cell lines and defective
erythropoietin
production delayed recovery of adequate erythropoietic activity. This correlated with an alteration of renal function only in those patients remaining
erythropoietin
deficient beyond day 180. However, supranormal
erythropoietin
levels in
interstitial pneumonia
suggests that
erythropoietin
response to hypoxia is not abrogated. CMV infection could also affect erythropoiesis through
erythropoietin
production after ABMT as well as allogeneic BMT. It is concluded that after ABMT the development of erythropoiesis is determined by the overall marrow proliferative activity and
erythropoietin
plays only a facilitating role. After allogeneic BMT, erythropoiesis depends on
erythropoietin
levels which remain inadequate for prolonged periods of time. The results suggest that the administration of recombinant human
erythropoietin
could reduce transfusion requirements after BMT.
...
PMID:Dynamics of erythropoietic recovery following bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. 848 76